Evidence map›Paper›PMID 33734968›Full record

ArticleClinical and experimental rheumatology

Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA.

Shobana Sankar, Mirette Habib, Sara Jaafar, Vivek Nagaraja, David Roofeh, Amber Young, Suiyuan Huang, Dinesh Khanna

Open access · bronzeAbstract read
In one paragraph

Article in Clinical and experimental rheumatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shobana SankarDepartment of Medicine, William Beaumont Hospital, Royal Oak, USA.
Mirette HabibDivision of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, USA.
Sara JaafarDivision of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, USA.
Vivek NagarajaDivision of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, USA.
David RoofehDivision of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, USA.
Amber YoungDivision of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, USA.
Suiyuan HuangDivision of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, and School of Public Health, University of Michigan Medical School, Ann Arbor, USA.
Dinesh KhannaDivision of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, USA. khannad@med.umich.edu.
University of Michigan–Ann Arbor · USCenter for Rheumatology · US

Funding

TRAINING OF ARTHRITIS RESEARCH SCIENTISTST32AR007080 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jason Knight · 1986 to 2026
$6.3M
Outcomes Research in Rheumatic DiseasesK24AR063120 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2012 to 2022
$1.6M
Systemic Sclerosis-Associated Interstitial Lung Disease Response IndexR01AR070470 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2017 to 2019
$642k
NIAMS NIH HHS K24 AR063120NIAMS NIH HHS R01 AR070470NIAMS NIH HHS T32 AR007080
6 · The paper itself

Abstract

objectivesTo determine the primary reason for hospitalisations in systemic sclerosis (SSc) and impact of underlying interstitial lung disease (ILD) in a tertiary scleroderma centre.

methodsA retrospective analysis on a subset of a scleroderma cohort from 2011-2019 was performed to assess causes for hospitalisations and mortality. A chart review was performed to extract demographics, primary reason for hospitalisation and inpatient mortality. Admissions were classified as SSc (if hospitalisation reason was related to primary organ dysfunction) and non-SSc related causes.

resultsThe mean age of the cohort was 53.1 years, 78% were women, and the mean disease duration was 5.2 years. Among 484 patients, 182 (37.6%) were admitted for a total of 634 admissions. In 382 SSc-related admissions, pulmonary hypertension (12.0%) and gastrointestinal dysmotility (11.0%), were major causes of urgent admissions; management of digital vasculopathy (26.1%) was the major reason for elective admissions. In 252 non-SSc related admissions, infection (respiratory:11.5%, skin and soft tissue: 6.3%) was the major reason for urgent admissions, and elective surgery (21.4%) was the major reason for elective admissions. We found 65% of all patients had underlying ILD and a greater proportion of patients with ILD were hospitalised (122 patients). Overall inpatient mortality was 9.3% and the leading cause for mortality was progressive pulmonary hypertension.

conclusionsAmong a large cohort of SSc patients who are followed at a tertiary scleroderma centre, 37.6 % had hospital admissions, while worsening pulmonary hypertension, ILD, cardiac involvement and infectious complications were the major cause of mortality and morbidity.

Indexed as

Hypertension, PulmonaryLung Diseases, InterstitialScleroderma, SystemicFemaleHospitalizationHumansMiddle AgedRetrospective Studies

Identifiers

PMID33734968
PMCPMC8324531
OpenAlexW3139082365

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.